Cargando…

Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma

BACKGROUND: BAP1 is a histone deubiquitinase that acts as a tumor and metastasis suppressor associated with disease progression in human cancer. We have used the “Calling Card System” of transposase-directed transposon insertion mapping to identify the genomic targets of BAP1 in uveal melanoma (UM)....

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Matthew, Qi, Zongtai, Chen, Xuhua, Cooper, John A., Mitra, Robi D., Onken, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219186/
https://www.ncbi.nlm.nih.gov/pubmed/30400891
http://dx.doi.org/10.1186/s12920-018-0424-0
_version_ 1783368609079230464
author Yen, Matthew
Qi, Zongtai
Chen, Xuhua
Cooper, John A.
Mitra, Robi D.
Onken, Michael D.
author_facet Yen, Matthew
Qi, Zongtai
Chen, Xuhua
Cooper, John A.
Mitra, Robi D.
Onken, Michael D.
author_sort Yen, Matthew
collection PubMed
description BACKGROUND: BAP1 is a histone deubiquitinase that acts as a tumor and metastasis suppressor associated with disease progression in human cancer. We have used the “Calling Card System” of transposase-directed transposon insertion mapping to identify the genomic targets of BAP1 in uveal melanoma (UM). This system was developed to identify the genomic loci visited by transcription factors that bind directly to DNA; our study is the first use of the system with a chromatin-remodeling factor that binds to histones but does not interact directly with DNA. METHODS: The transposase piggyBac (PBase) was fused to BAP1 and expressed in OCM-1A UM cells. The insertion of transposons near BAP1 binding sites in UM cells were identified by genomic sequencing. We also examined RNA expression in the same OCM-1A UM cells after BAP1 depletion to identify BAP1 binding sites associated with BAP1-responsive genes. Sets of significant genes were analyzed for common pathways, transcription factor binding sites, and ability to identify molecular tumor classes. RESULTS: We found a strong correlation between multiple calling-card transposon insertions targeted by BAP1-PBase and BAP1-responsive expression of adjacent genes. BAP1-bound genomic loci showed narrow distributions of insertions and were near transcription start sites, consistent with recruitment of BAP1 to these sites by specific DNA-binding proteins. Sequence consensus analysis of BAP1-bound sites showed enrichment of motifs specific for YY1, NRF1 and Ets transcription factors, which have been shown to interact with BAP1 in other cell types. Further, a subset of the BAP1 genomic target genes was able to discriminate aggressive tumors in published gene expression data from primary UM tumors. CONCLUSIONS: The calling card methodology works equally well for chromatin regulatory factors that do not interact directly with DNA as for transcription factors. This technique has generated a new and expanded list of BAP1 targets in UM that provides important insight into metastasis pathways and identifies novel potential therapeutic targets. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12920-018-0424-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6219186
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62191862018-11-16 Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma Yen, Matthew Qi, Zongtai Chen, Xuhua Cooper, John A. Mitra, Robi D. Onken, Michael D. BMC Med Genomics Research Article BACKGROUND: BAP1 is a histone deubiquitinase that acts as a tumor and metastasis suppressor associated with disease progression in human cancer. We have used the “Calling Card System” of transposase-directed transposon insertion mapping to identify the genomic targets of BAP1 in uveal melanoma (UM). This system was developed to identify the genomic loci visited by transcription factors that bind directly to DNA; our study is the first use of the system with a chromatin-remodeling factor that binds to histones but does not interact directly with DNA. METHODS: The transposase piggyBac (PBase) was fused to BAP1 and expressed in OCM-1A UM cells. The insertion of transposons near BAP1 binding sites in UM cells were identified by genomic sequencing. We also examined RNA expression in the same OCM-1A UM cells after BAP1 depletion to identify BAP1 binding sites associated with BAP1-responsive genes. Sets of significant genes were analyzed for common pathways, transcription factor binding sites, and ability to identify molecular tumor classes. RESULTS: We found a strong correlation between multiple calling-card transposon insertions targeted by BAP1-PBase and BAP1-responsive expression of adjacent genes. BAP1-bound genomic loci showed narrow distributions of insertions and were near transcription start sites, consistent with recruitment of BAP1 to these sites by specific DNA-binding proteins. Sequence consensus analysis of BAP1-bound sites showed enrichment of motifs specific for YY1, NRF1 and Ets transcription factors, which have been shown to interact with BAP1 in other cell types. Further, a subset of the BAP1 genomic target genes was able to discriminate aggressive tumors in published gene expression data from primary UM tumors. CONCLUSIONS: The calling card methodology works equally well for chromatin regulatory factors that do not interact directly with DNA as for transcription factors. This technique has generated a new and expanded list of BAP1 targets in UM that provides important insight into metastasis pathways and identifies novel potential therapeutic targets. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12920-018-0424-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-06 /pmc/articles/PMC6219186/ /pubmed/30400891 http://dx.doi.org/10.1186/s12920-018-0424-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yen, Matthew
Qi, Zongtai
Chen, Xuhua
Cooper, John A.
Mitra, Robi D.
Onken, Michael D.
Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title_full Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title_fullStr Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title_full_unstemmed Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title_short Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma
title_sort transposase mapping identifies the genomic targets of bap1 in uveal melanoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219186/
https://www.ncbi.nlm.nih.gov/pubmed/30400891
http://dx.doi.org/10.1186/s12920-018-0424-0
work_keys_str_mv AT yenmatthew transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma
AT qizongtai transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma
AT chenxuhua transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma
AT cooperjohna transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma
AT mitrarobid transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma
AT onkenmichaeld transposasemappingidentifiesthegenomictargetsofbap1inuvealmelanoma